Satellos Bioscience Inc. (NASDAQ:MSLE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.60.
A number of analysts have issued reports on MSLE shares. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Satellos Bioscience in a research note on Monday, August 17th. Zacks Research cut shares of Satellos Bioscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 21st. Craig Hallum assumed coverage on shares of Satellos Bioscience in a report on Thursday, October 8th. They issued a “buy” rating and a $24.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a report on Wednesday, November 4th. Finally, Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday.
Check Out Our Latest Stock Report on Satellos Bioscience
Satellos Bioscience Stock Performance
Shares of Satellos Bioscience stock opened at $6.47 on Tuesday. The business’s 50 day moving average price is $7.72 and its 200 day moving average price is $8.18. The company has a market cap of $137.29 million, a price-to-earnings ratio of -3.10 and a beta of 1.63. Satellos Bioscience has a one year low of $5.44 and a one year high of $13.39.
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). On average, analysts predict that Satellos Bioscience will post -1.86 EPS for the current fiscal year.
Institutional Trading of Satellos Bioscience
A hedge fund recently raised its stake in Satellos Bioscience stock. Stonepine Capital Management LLC boosted its holdings in Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 391.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 491,624 shares of the company’s stock after acquiring an additional 391,624 shares during the period. Satellos Bioscience accounts for about 0.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned approximately 2.36% of Satellos Bioscience worth $3,723,291 at the end of the most recent quarter.
About Satellos Bioscience
Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.
Featured Stories
- Five stocks we like better than Satellos Bioscience
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
